United States Steel & Carnegie Pension Fund held its stake in Johnson & Johnson (NYSE:JNJ) during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 796,840 shares of the company’s stock at the end of the first quarter. Johnson & Johnson accounts for 3.0% of United States Steel & Carnegie Pension Fund’s investment portfolio, making the stock its 4th largest position. United States Steel & Carnegie Pension Fund’s holdings in Johnson & Johnson were worth $99,246,000 as of its most recent SEC filing.
Other hedge funds have also added to or reduced their stakes in the company. Lenox Wealth Advisors Inc. raised its stake in shares of Johnson & Johnson by 0.7% in the first quarter. Lenox Wealth Advisors Inc. now owns 871 shares of the company’s stock worth $108,000 after buying an additional 6 shares during the last quarter. Thomas J. Herzfeld Advisors Inc. purchased a new stake in shares of Johnson & Johnson during the fourth quarter worth approximately $117,000. Empirical Finance LLC bought a new position in shares of Johnson & Johnson during the fourth quarter worth about $144,000. Foundation Resource Management Inc. bought a new position in shares of Johnson & Johnson during the first quarter worth about $204,000. Finally, Arbor Investment Advisors LLC bought a new position in shares of Johnson & Johnson during the first quarter worth about $215,000. 66.01% of the stock is currently owned by institutional investors and hedge funds.
Johnson & Johnson (JNJ) traded down 0.13% during trading on Friday, hitting $133.18. The stock had a trading volume of 3,192,805 shares. The company has a 50-day moving average of $133.33 and a 200 day moving average of $125.48. The firm has a market cap of $358.76 billion, a P/E ratio of 22.53 and a beta of 0.78. Johnson & Johnson has a 52-week low of $109.32 and a 52-week high of $137.08.
Johnson & Johnson (NYSE:JNJ) last issued its quarterly earnings results on Tuesday, July 18th. The company reported $1.83 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $1.79 by $0.04. Johnson & Johnson had a net margin of 20.31% and a return on equity of 21.58%. The company had revenue of $18.84 billion during the quarter, compared to analysts’ expectations of $18.94 billion. During the same quarter last year, the company posted $1.74 EPS. The firm’s revenue was up 1.9% compared to the same quarter last year. On average, equities research analysts predict that Johnson & Johnson will post $7.18 earnings per share for the current fiscal year.
The firm also recently declared a quarterly dividend, which will be paid on Tuesday, September 12th. Shareholders of record on Tuesday, August 29th will be given a $0.84 dividend. The ex-dividend date of this dividend is Friday, August 25th. This represents a $3.36 annualized dividend and a yield of 2.52%. Johnson & Johnson’s dividend payout ratio is presently 56.76%.
ILLEGAL ACTIVITY WARNING: “Johnson & Johnson (JNJ) is United States Steel & Carnegie Pension Fund’s 4th Largest Position” was originally posted by Transcript Daily and is owned by of Transcript Daily. If you are viewing this story on another site, it was copied illegally and republished in violation of U.S. and international trademark & copyright legislation. The correct version of this story can be read at https://transcriptdaily.com/2017/08/06/united-states-steel-carnegie-pension-fund-has-99246000-position-in-johnson-johnson-jnj-updated-updated.html.
A number of equities analysts have recently issued reports on JNJ shares. BidaskClub upgraded Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a report on Saturday, June 17th. Jefferies Group LLC restated a “hold” rating and set a $135.00 price objective (down previously from $140.00) on shares of Johnson & Johnson in a report on Sunday, May 14th. Royal Bank Of Canada restated a “buy” rating and set a $128.00 price objective on shares of Johnson & Johnson in a report on Thursday, June 15th. Atlantic Securities cut Johnson & Johnson from a “neutral” rating to an “underweight” rating and set a $113.00 target price on the stock. in a research report on Friday, July 21st. Finally, Barclays PLC reaffirmed an “equal weight” rating and set a $130.00 target price (up previously from $125.00) on shares of Johnson & Johnson in a research report on Monday, April 17th. Three investment analysts have rated the stock with a sell rating, nine have issued a hold rating and eleven have assigned a buy rating to the stock. The stock presently has an average rating of “Hold” and an average target price of $133.72.
In other Johnson & Johnson news, VP Dominic J. Caruso sold 82,591 shares of the firm’s stock in a transaction that occurred on Thursday, July 20th. The shares were sold at an average price of $136.72, for a total value of $11,291,841.52. Following the completion of the transaction, the vice president now owns 226,693 shares of the company’s stock, valued at approximately $30,993,466.96. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, VP Paulus Stoffels sold 102,692 shares of Johnson & Johnson stock in a transaction on Monday, July 24th. The stock was sold at an average price of $133.14, for a total transaction of $13,672,412.88. Following the sale, the vice president now directly owns 230,342 shares of the company’s stock, valued at $30,667,733.88. The disclosure for this sale can be found here. Company insiders own 0.19% of the company’s stock.
About Johnson & Johnson
Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. It operates through three segments: Consumer, Pharmaceutical and Medical Devices. Its primary focus is products related to human health and well-being.
Receive News & Ratings for Johnson & Johnson Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Johnson & Johnson and related companies with MarketBeat.com’s FREE daily email newsletter.